ATS 2019 Virtual Final Program

408 Exhaled Small, Polar, Energetics-Related Metabolites by GC-MS for Lung Cancer Risk Assessment/ S.D. Spivack, M. Shi, D. Patel, A. Desai, J.B. Dobkin, C. Shah, D. Hosgood, K. Ye, Y. Qiu, I. Kurland, Bronx, NY, p.A5816 409 Xeroderma Pigmentosum Group C (XPC) Is Reduced in Human Lung Adenocarcinoma/ B. Lee, E.A. Mickler, R.S. Stearman, M.W. Geraci, C.R. Sears, Indianapolis, IN, p.A5817 410 Plasma CK-19 Expressions Can Differentiate High Risk COPD from Lung Cancer/ S. Umekawa, K. Almodovar, S. Tonthat, S. Lee, M.H.J. Lee, S. Khanolkar, D. Upadhyay, Fresno, CA, p.A5818 411 Potentially Functional Genetic Variants in the TNF/TNFR Signaling Pathway Genes Predict Survival of Non-Small Cell Lung Cancer Patients in the PLCO Cancer Screening Trial and mRNA Expression Levels in the TCGA/ Y. Guo, Y. Feng, H. Liu, Q. Wei, Shanghai, China, p.A5819 412 Prognostic Value of EPPK1 Molecular Alterations in Non-Small Cell Lung Cancer/ K. Arimura, J. Qian, Y. Zou, J.S.M. Rahman, P.P. Massion, Nashville, TN, p.A5820 413 Effect of the ABCG2 C421A Polymorphism on Plasma Concentration of Gefitinib/ S. Sakamoto, K. Sato, Y. Okuda, Y. Izumiya, N. Kumagai, K. Sudo, M. Asano, M. Takeda, M. Sano, K. Nakayama, Akita, Japan, p.A5821 414 Increased miRNA-30a Levels in Bronchoalveolar Lavage Fluid as a Diagnostic Biomarker for Lung Cancer/ W. Zhu, Chengdu, China, p.A5822 415 Correlation of Pretreatment Neutrophil to Lymphocyte Ratio and Clinical Outcomes in Patients with Lung Cancer Receiving Immunotherapy/ J. Jin, D. Liu, P.W. Tian, W.M. Li, Chengdu, China, p.A5823 416 TOP2A and HER2neu Evaluation in Malignant Pleural Mesothelioma/ F.M.A. Abou Elkasem, M. Rahouma, I. Loay, O. Badawi, M. Kamel, D.A. Ibrahim, G. Ghaly, M. Amin, A.M. Abdelrahman, Cairo, Egypt, p.A5824 417 The Impact of a Bronchial Genomic Classifier in Patients Evaluated for Peripheral Pulmonary Nodules with Electromagnetic Navigational Bronchoscopy/ S. Awadallah, H. Sarwar, M.R. Bowling, Greenville, NC, p.A5825 418 Interaction of Estrogen Receptor ß5 and Interleukin 6 Receptor in the Progression of Non-Small Cell Lung Cancer/ J. Zhao, H. Tang, Y. Bai, L. Xiong, L. Zhang, Wuhan, China, p.A5826 419 Clinical Potential of Sputum in Detecting Driver Mutations in Patients with Non-Small Cell Lung Cancer: A Preliminary Study/ V. De Sa, C.A. De Paula, H.C. Freitas, G. Torrenzan, D.M. Carraro, Sao Paulo, Brazil, p.A5827 420 Density of PD-1 Positive T-Cells from Resected Tumor Specimens Analyzed by Multiplex Immunohistochemistry Can Predict Recurrence in Lung Adenocarcinoma/ T. Atwater, P.P. Massion, Nashville, TN, p.A5828 421 Blinded Prospective Validation Study of a Whole Blood Gene-Expression Classifier for the Diagnosis of Benign Versus Malignant Pulmonary Nodules/ P. McQuary, M. Shahbazian, L. Friedman, N. Sheibani, M. Del Rosario, E. Nith, K. Copeland, B. Ring, D. Harrington, L. Hesterberg, Alameda, CA, p.A7450 422 Prospective Early Detection of Lung Cancer in COPD Patients by Electronic Nose Analysis of Exhaled Breath/ R. de Vries, J.M. van den Heuvel, Y.W.F. Dagelet, E. Dijkers, T. Fabius, F.H.C. de Jongh, P.M.C. Jak, E.G. Haarman, S. Kester, M. Bekkers, M.M. van den Heuvel, P. Baas, J.C.C.M. in t Veen, A.H. Maitland-van der Zee, P.J. Sterk, Amsterdam, Netherlands, p.A7451 423 Novel Multiplexed Plasma Biomarkers and Clinical Factors Augment Risk Assessment for Indeterminate Pulmonary Nodules in Former Smokers/ A. Fish, A. Vachani, P. Massion, S. Antic, N. Trivedi, J.K. Brown, T.K. Rubenstein, A.D. Rostykus, M. Beggs, H. Yu, L. Carbonell, M. Arjomandi, Milpitas, CA, p.A7452 ATS 2019 • Dallas, TX 310 TUESDAY • MAY 21 4:30 p.m.-6:30 p.m. SECTION MEMBERSHIP MEETINGS The Section meetings are open to all ATS members and other interested individuals. Items to be discussed include the Sections’ current projects and future directions. MEDICAL EDUCATION Hyatt Regency, Dallas Cumberland A-C (Exhibition Level) Chairing: Henry Fessler, MD, Baltimore, MD W. Graham Carlos, MD, MSCR, ATSF, Indianapolis, IN TERRORISM AND INHALATION DISASTERS Hyatt Regency Dallas Windsor (Atrium Level) Chairing: Sven Jordt, PhD, Chapel Hill, NC Erik Svendsen, PhD, Atlanta, GA